FDA accepts Opus Genetics’ presbyopia treatment application

Opus Genetics Inc. (NASDAQ:IRD) announced today that the U.S. Food and Drug Administration has accepted its supplemental New Drug Application for phentolamine ophthalmic solution 0.75%, a treatment for presbyopia, from its headquarters in Research Triangle Park, N.C. This regulatory acceptance marks a significant milestone for the biopharmaceutical company as it progresses toward potentially bringing a new treatment option to market for the millions of Americans experiencing age-related farsightedness. The application acceptance means the submission is now formally under review by the FDA, though the timeline for potential approval remains undetermined. Presbyopia, a natural condition that typically becomes noticeable around age 40, causes difficulty with near vision tasks such as reading and has traditionally been addressed with reading glasses or corrective lenses. Phentolamine ophthalmic solution 0.75% works by temporarily relaxing the ciliary muscle in the eye, potentially restoring near vision capabilities without the need for visual aids.